Ibs clinical trials

Explore recruiting ibs clinical trials.

Recruiting ibs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ibs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

ICEBOAT. A prospective, multi-center, double blind randomized trial of fecal microbiota transplantation (FMT) delivered by capsule versus placebo in severe irritable bowel syndrome (IBS)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of Saccharomyces boulardii CNCM I-745 in adult patients with non-constipated Irritable Bowel Syndrome.

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIVEDIFF

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Ibs trials by city

Ibs in Toronto Ibs in Vancouver Ibs in Montreal Ibs in Calgary Ibs in Edmonton Ibs in Ottawa Ibs in Winnipeg Ibs in Quebec City Ibs in Hamilton Ibs in Kitchener Ibs in London Ibs in Halifax Ibs in New York Ibs in Los Angeles Ibs in Chicago Ibs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease